7/20/2020, 8:17 AM (Source: TeleTrader)
more TeleTrader news

GSK, CureVac partner on vaccine development

GlaxoSmithKline plc (GSK) and CureVac agreed to become strategic partners on mRNA vaccines and monoclonal antibodies for infectious diseases, the companies said in a statement released on Monday. GSK will be in charge of research and development activities while CureVac will focus on pre-clinical and clinical development as well as commercialization and manufacturing.

The deal includes an equity investment by GSK in CureVac worth £130 million, an upfront payment of £104 million in cash and £26 million for manufacturing capacity verification in Germany, which is a one-time reimbursable payment. CureVac will be eligible to also get over £600 million linked to regulatory and commercial milestones as well as tiered royalties on product sales.

"GSK’s self-amplifying mRNA (SAM) vaccine technology has shown us the potential of mRNA technology to advance the science of vaccine development, and CureVac’s experience complements our own expertise," GSK vaccines president, Roger Connor said.

Breaking the News / VP